Metabolic Effects of Antipsychotics in Children

Related Clinical Trial
Monitoring of Sleep and Behavior of Children 3-7 Years Old Receiving Parent-Child Interaction Therapy With the Help of Artificial Intelligence Symptoms and Mechanisms of Child Psychiatric Disorders Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances Randomized Feasibility Trial of Mind My Mind Metabolic Effects of Antipsychotics in Children Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to Collaborative Care for Children’s Mental Health Problems Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges Addressing Depression and Positive Parenting Techniques (ADAPT) Child and Family Outcomes and Consumer Satisfaction for Online vs Staff-Delivered Parenting Intervention Phone-Delivered Psychological Intervention (t-CETA) for Mental Health Problems in 8-17 Year-Old Syrian Refugee Children Mindful Parenting and Parent Training Program Study Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder Enhanced Support for Behavioral Barriers to Learning: An Evaluation of the SCHOOL STARS Program Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder Correlating Real and Virtual World Behavioral Fluctuations in Adolescence Evaluating an Online Parenting Support System Disseminated by Pediatric Practices Study of Cognition and Control in Youths Treatment of Conduct Problems and Depression The Effectiveness of Parent-Child Interaction Therapy (PCIT) School-Based Mental Health Services for Urban Children A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation Investigation of Psychophysiological Response to Aversive Stimuli Over Time With Omega-3 Investigation of Psychophysiological Correlation of Aggression and Response to Aversive Stimuli Behavioral Sleep Intervention in Children With Disruptive Behaviors Arousal-Biofeedback for the Treatment of Aggressive Behavior in Children and Adolescents Strongest Families Ontario (Formerly the Family Help Program) On-line Treatment for Conduct Problems Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits A Study of the Safety and Effectiveness of Risperidone Versus Placebo for the Treatment of Conduct Disorder in Children With Mild, Moderate, or Borderline Mental Retardation Supplements and Social Skills Intervention Study Evaluating the Feasibility of Internet-delivered PCIT Resources to Enhance the Adjustment of Children (REACH) Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders Treatment of Children With Peer Related Aggressive Behavior (ScouT) Prevention of Oppositional Defiant and Conduct Disorders in Preschool Children Preschool First Step to Success: An Efficacy Replication Study Home Based Treatment for Drug Use in Early Adolescents Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders Mindfulness-based Program for Children With Disruptive Behavior Disorder Guided Self-Help for Parents of Children With Externalizing Problem Behavior Randomized Controlled Trial of Comet Via the Internet or in Group Format. An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD). Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder Evaluation of Regulation Focused Psychotherapy for Children Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions Multi-Family Group Therapy for Reducing Behavioral Difficulties in Youth Treatment of Children With Peer Related Aggressive Behavior

Brief Title

Metabolic Effects of Antipsychotics in Children

Official Title

Metabolic Effects of Antipsychotics in Children

Brief Summary

      The project aims to describe and compare the outcome of 12 weeks of prospective, randomized
      treatment with olanzapine, risperidone or aripiprazole on insulin action in skeletal muscle,
      liver and adipose tissue, abdominal fat mass, total body and fat-free mass, efficacy for
      symptoms of aggression and non-metabolic adverse events. Children aged 6-18 will be studied,
      exploring effects of stimulant therapy and age-related differences in vulnerability to
      treatment-induced adverse metabolic changes. Aims are addressed by measuring glucose and
      lipid kinetics with stable isotope tracers, body composition with dual energy x-ray
      absorptiometry and magnetic resonance imaging (MRI), and standardized assessments of efficacy
      and adverse events. Relevant data are critically needed to target clinical therapy and basic
      research, identify medical risks, and guide regulatory decisions in this vulnerable

Detailed Description

      This randomized clinical trial assesses both the safety and efficacy of atypical
      antipsychotic agents in antipsychotic-naive aggressive children with various childhood
      psychiatric disorders during 12 weeks of prospective, randomized treatment with olanzapine,
      risperidone or aripiprazole.

      Aim 1: To evaluate effects of selected antipsychotic treatments on insulin action in muscle
      (glucose disposal), liver (glucose production) and adipose tissue (lipolysis).

      Aim 2: To evaluate effects of selected antipsychotic treatments on abdominal fat mass, total
      body fat and total fat-free mass.

Study Phase

Phase 4

Study Type


Primary Outcome

Change in DEXA % Body Fat

Secondary Outcome

 Change in Insulin-stimulated Glycerol Rate of Appearance (Glycerol Ra)





Study Arms / Comparison Groups

Description:  Participants in this group will be randomized to flexibly-dosed treatment with aripiprazole.


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

April 2006

Completion Date

July 2011

Primary Completion Date

March 2011

Eligibility Criteria

        Inclusion Criteria:

          -  Aged 6-18 years

          -  Generally healthy and a score of ≥ 18 on the Aberrant Behavior Checklist in the
             context of one or more Axis I Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition (DSM-IV) childhood psychiatric disorders, including conduct disorder,
             oppositional defiant disorder, disruptive behavior disorder, autism, pervasive
             developmental disorder, attention deficit disorder, schizophrenia and bipolar
             affective disorders

          -  Children's Global Assessment Scale (CGAS) score ≤ 60

          -  Not previously treated with an antipsychotic; individual subjects with remote, brief
             prior antipsychotic exposure may be considered for enrollment by the PI on a case by
             case basis

          -  Patient assent and informed consent obtained from the parent or guardian

          -  No clinically significant (based on PI determination) changes in permitted medications
             (e.g., stimulants and selective serotonin reuptake inhibitors [SSRIs]) for
             approximately 1 month prior to Baseline evaluations

        Exclusion Criteria:

          -  Active suicidality or primary dx of major depressive disorder

          -  Any lifetime use of antipsychotics or non-serotonin selective reuptake inhibitor
             (non-SSRI) anti-depressants

          -  The presence of any serious medical disorder, based on PI determination, that may
             confound the assessment of relevant biologic measures or diagnoses, including:

               -  significant organ system dysfunction;

               -  endocrine disease, including type 1 or type 2 diabetes mellitus;

               -  coagulopathy;

               -  anemia;

               -  or acute infection.

          -  Subjects regularly taking any glucose lowering agent, lipid lowering agent, exogenous
             testosterone, recombinant human growth hormone, or any other endocrine agent that
             might confound substrate metabolism, oral glucocorticoids (glucocorticoid inhalants
             and nasal sprays are permitted), antihistamines, sedating antihistamines (non-sedating
             antihistamines such as but not limited to Claritin (loratadine) and Zyrtec
             (cetirizine) are permitted), and certain mood stabilizing agents, as some medications
             may themselves worsen or otherwise alter weight gain, glucose and lipid regulation or
             otherwise make it difficult to assess the effects of the antipsychotic alone; (note
             that exposure to many psychotropic agents including stimulants and SSRI's is permitted
             in order to maintain the generalizability of the sample);

          -  Intelligence quotient (IQ) < 70 (based on school records and/or evaluation by

          -  current substance abuse

          -  Past history or currently has dyskinesia

          -  Stimulant dosage significantly higher (per PI judgment)than the equivalent of
             approximately 2mg/kg/day methylphenidate equivalent dose.




6 Years - 18 Years

Accepts Healthy Volunteers



John W. Newcomer, MD, , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Secondary IDs


Responsible Party


Study Sponsor

Washington University School of Medicine


 National Institute of Mental Health (NIMH)

Study Sponsor

John W. Newcomer, MD, Principal Investigator, Florida Atlantic University and Washington University School of Medicine

Verification Date

June 2018